Deutsche Bank Lowers Diasorin to Sell, Cuts Target to €58 Citing 2026 Guidance Risk
Deutsche Bank downgraded Diasorin to a sell rating and reduced its price target to €58 from €62, warning that the diagnostics group's 2026 guidance and 2030 targets rely on optimistic assumptions. The bank models lower adjusted EBITDA versus consensus, questions the feasibility of a sharp second-half sales ramp and flags multiple regional and produ…